|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
et al: Adjuvant chemotherapy with gemcitabine vs. observation in
patients undergoing curative-intent resection of pancreatic cancer:
A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Diab M, Muqbil I, Mohammad RM, Azmi AS and
Philip PA: The role of microRNAs in the diagnosis and treatment of
pancreatic adenocarcinoma. J Clin Med. 5:E592016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yonemori K, Kurahara H, Maemura K and
Natsugoe S: MicroRNA in pancreatic cancer. J Hum Genet. 62:33–40.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tan Z, Zhao J and Jiang Y: MiR-634
sensitizes glioma cells to temozolomide by targeting CYR61 through
Raf-ERK signaling pathway. Cancer Med. 7:913–921. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo J, Zhang CD, An JX, Xiao YY, Shao S,
Zhou NM and Dai DQ: Expression of miR-634 in gastric carcinoma and
its effects on proliferation, migration, and invasion of gastric
cancer cells. Cancer Med. 7:776–787. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang CZ, Cao Y, Fu J, Yun JP and Zhang
MF: miR-634 exhibits anti-tumor activities toward hepatocellular
carcinoma via Rab1A and DHX33. Mol Oncol. 10:1532–1541. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van Jaarsveld MT, van Kuijk PF, Boersma
AW, Helleman J, van IJcken WF, Mathijssen RH, Pothof J, Berns EM,
Verweij J and Wiemer EA: miR-634 restores drug sensitivity in
resistant ovarian cancer cells by targeting the Ras-MAPK pathway.
Mol Cancer. 14:1962015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cong J, Liu R, Wang X, Jiang H and Zhang
Y: MiR-634 decreases cell proliferation and induces apoptosis by
targeting mTOR signaling pathway in cervical cancer cells. Artif
Cells Nanomed Biotechnol. 44:1694–1701. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peng X, Cao P, He D, Han S, Zhou J, Tan G,
Li W, Yu F, Yu J, Li Z and Cao K: miR-634 sensitizes nasopharyngeal
carcinoma cells to paclitaxel and inhibits cell growth both in
vitro and in vivo. Int J Clin Exp Pathol. 7:6784–6791.
2014.PubMed/NCBI
|
|
13
|
Chun YS, Pawlik TM and Vauthey JN: 8th
edition of the AJCC cancer staging manual: Pancreas and
hepatobiliary cancers. Ann Surg Oncol. 25:845–847. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhai LL, Xie Q, Zhou CH, Huang DW, Tang ZG
and Ju TF: Overexpressed HSPA2 correlates with tumor angiogenesis
and unfavorable prognosis in pancreatic carcinoma. Pancreatology.
17:457–463. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang H, Gao H, Liu C, Kong Y, Wang C and
Zhang H: Expression and clinical significance of HSPA2 in
pancreatic ductal adenocarcinoma. Diagn Pathol. 10:132015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dix DJ, Allen JW, Collins BW,
Poorman-Allen P, Mori C, Blizard DR, Brown PR, Goulding EH, Strong
BD and Eddy EM: HSP70-2 is required for desynapsis of synaptonemal
complexes during meiotic prophase in juvenile and adult mouse
spermatocytes. Development. 124:4595–4603. 1997.PubMed/NCBI
|
|
18
|
Scieglinska D and Krawczyk Z: Expression,
function, and regulation of the testis-enriched heat shock HSPA2
gene in rodents and humans. Cell Stress Chaperones. 20:221–235.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fu Y, Zhao H, Li XS, Kang HR, Ma JX, Yao
FF and Du N: Expression of HSPA2 in human hepatocellular carcinoma
and its clinical significance. Tumour Biol. 35:11283–11287. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang H, Chen W, Duan CJ and Zhang CF:
Overexpression of HSPA2 is correlated with poor prognosis in
esophageal squamous cell carcinoma. World J Surg Oncol. 11:1412013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scieglinska D, Gogler-Piglowska A,
Butkiewicz D, Chekan M, Malusecka E, Harasim J, Habryka A and
Krawczyk Z: HSPA2 is expressed in human tumors and correlates with
clinical features in non-small cell lung carcinoma patients.
Anticancer Res. 34:2833–2840. 2014.PubMed/NCBI
|
|
22
|
Garg M, Kanojia D, Saini S, Suri S, Gupta
A, Surolia A and Suri A: Germ cell-specific heat shock protein 70-2
is expressed in cervical carcinoma and is involved in the growth,
migration, and invasion of cervical cells. Cancer. 116:3785–3796.
2010. View Article : Google Scholar : PubMed/NCBI
|
